EyePoint Pharmaceuticals, Inc.EYPTNASDAQ
Loading
EV to Sales: Premium ValuationElevated
Percentile Rank93
3Y CAGR+173.3%
5Y CAGR+76.5%
Year-over-Year Change
Enterprise value to sales ratio
3Y CAGR
+173.3%/yr
vs -47.2%/yr prior
5Y CAGR
+76.5%/yr
Recent acceleration
Acceleration
+220.4pp
Accelerating
Percentile
P93
Near historical high
vs 5Y Ago
17.1x
Strong expansion
Streak
1 yr
Consecutive growthElevated
| Period | Value | YoY Change |
|---|---|---|
| 2025 | 40.08 | +407.7% |
| 2024 | 7.89 | -39.4% |
| 2023 | 13.03 | +563.5% |
| 2022 | 1.96 | -65.9% |
| 2021 | 5.76 | +146.1% |
| 2020 | 2.34 | -74.9% |
| 2019 | 9.33 | -63.0% |
| 2018 | 25.22 | +212.5% |
| 2017 | 8.07 | -82.4% |
| 2016 | 45.79 | - |